Teva Sues Mylan, Others Over Proposed Azilect Generic

Law360, New York (October 5, 2010, 6:48 PM EDT) -- Teva Pharmaceutical Industries Ltd. filed suit on Tuesday against several generics makers in an attempt to prevent off-label versions of its Parkinson's disease treatment Azilect from hitting drugstore shelves prior to the expiration of a patent covering the drug.

The company filed suit against three generics companies – Watson Pharmaceuticals Inc., Mylan Inc. and Orchid Chemicals & Pharmaceuticals Ltd. – in the U.S. District Court for the District of New Jersey, alleging infringement of U.S. Patent Number 5,453,466, according to a filing with the U.S. Securities...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.